NCT02463799 - Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 22, 2016

Primary Completion Date

December 12, 2019

Study Completion Date

December 12, 2019

Conditions

Prostate Cancer

Interventions

DRUG

Radium-223

6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223

BIOLOGICAL

Sipuleucel-T

3 infusions of sipuleucel-T alone

Trial Locations (5)

Sibley Memorial Hospital, Washington D.C.

Johns Hopkins Hospital, Baltimore

Duke University, Durham

Tulane Cancer Center, New Orleans

Cedars-Sinai Medical Center, Los Angeles